Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Asset Utilization Ratio: 2011-2025

Historic Asset Utilization Ratio for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to 0.64.

  • Heron Therapeutics' Asset Utilization Ratio rose 2.74% to 0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64, marking a year-over-year increase of 2.74%. This contributed to the annual value of 0.63 for FY2024, which is 18.01% up from last year.
  • Heron Therapeutics' Asset Utilization Ratio amounted to 0.64 in Q3 2025, which was up 0.77% from 0.64 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Asset Utilization Ratio ranged from a high of 0.64 in Q3 2025 and a low of 0.23 during Q3 2021.
  • For the 3-year period, Heron Therapeutics' Asset Utilization Ratio averaged around 0.60, with its median value being 0.63 (2024).
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first fell by 15.83% in 2021, then soared by 67.06% in 2022.
  • Heron Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.26 in 2021, then skyrocketed by 56.94% to 0.41 in 2022, then skyrocketed by 36.59% to 0.56 in 2023, then climbed by 13.02% to 0.64 in 2024, then increased by 2.74% to 0.64 in 2025.
  • Its Asset Utilization Ratio stands at 0.64 for Q3 2025, versus 0.64 for Q2 2025 and 0.63 for Q1 2025.